Form 8-K - Current report:
SEC Accession No. 0001140361-23-057484
Filing Date
2023-12-13
Accepted
2023-12-13 16:30:20
Documents
12
Period of Report
2023-12-13
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ef20016537_8k.htm   iXBRL 8-K 37089
  Complete submission text file 0001140361-23-057484.txt   174163

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20231213.xsd EX-101.SCH 3859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20231213_lab.xml EX-101.LAB 22546
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20231213_pre.xml EX-101.PRE 16040
6 EXTRACTED XBRL INSTANCE DOCUMENT ef20016537_8k_htm.xml XML 4035
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 231484369
SIC: 2834 Pharmaceutical Preparations